L H Zhao1, Q L Lin1, J Wei1, Y L Huai1, K J Wang1, H Y Yan1. 1. Department of Pathology, Beijing Civil Aviation Hospital 1 Gao Jing Jia, Chao Yang District, Beijing 100123, China.
Abstract
BACKGROUND: Currently, it is difficult to predict the prognosis of patients exhibiting stage II or stage III colorectal cancer (CRC) and to identify those patients most likely to benefit from aggressive treatment. The current study was performed to examine the clinicopathological significance of CD44 and CD44v6 protein expression in these patients. STUDY DESIGN: We retrospectively investigated 187 consecutive patients who underwent surgery with curative intent for stage II to III CRC from 2007 to 2013 in the Beijing Civil Aviation Hospital. CD44 and CD44v6 protein expression levels were determined using immunohistochemistry and compared to the clinicopathological data. RESULTS: Using immunohistochemical detection, CD44 expression was observed in 108 (57.75%) of the CRC patients; and its detection was significantly associated with greater invasion depth, lymph node metastasis, angiolymphatic invasion, and a more advanced pathological tumor-lymph node-metastasis (TNM) stage. CD44v6 expression was observed in 135 (72.19%) of the CRC patients; and its expression was significantly associated with a poorly differentiated histology, greater invasion depth, lymph node metastasis, angiolymphatic invasion, and a more advanced pathological TNM stage. Expression of CD44v6 was higher than that of CD44 in stage II and stage III sporadic CRC. CONCLUSION: CD44v6 is a more useful marker for predicting a poor prognosis in stage II and stage III sporadic CRC as compared to CD44.
BACKGROUND: Currently, it is difficult to predict the prognosis of patients exhibiting stage II or stage III colorectal cancer (CRC) and to identify those patients most likely to benefit from aggressive treatment. The current study was performed to examine the clinicopathological significance of CD44 and CD44v6 protein expression in these patients. STUDY DESIGN: We retrospectively investigated 187 consecutive patients who underwent surgery with curative intent for stage II to III CRC from 2007 to 2013 in the Beijing Civil Aviation Hospital. CD44 and CD44v6 protein expression levels were determined using immunohistochemistry and compared to the clinicopathological data. RESULTS: Using immunohistochemical detection, CD44 expression was observed in 108 (57.75%) of the CRC patients; and its detection was significantly associated with greater invasion depth, lymph node metastasis, angiolymphatic invasion, and a more advanced pathological tumor-lymph node-metastasis (TNM) stage. CD44v6 expression was observed in 135 (72.19%) of the CRC patients; and its expression was significantly associated with a poorly differentiated histology, greater invasion depth, lymph node metastasis, angiolymphatic invasion, and a more advanced pathological TNM stage. Expression of CD44v6 was higher than that of CD44 in stage II and stage III sporadic CRC. CONCLUSION: CD44v6 is a more useful marker for predicting a poor prognosis in stage II and stage III sporadic CRC as compared to CD44.
Authors: R Bendardaf; A Algars; A Elzagheid; E Korkeila; R Ristamäki; H Lamlum; Y Collan; K Syrjänen; S Pyrhönen Journal: Oncol Rep Date: 2006-10 Impact factor: 3.906
Authors: Jongmin Park; Jun Seok Park; Chen-Han Huang; Ala Jo; Kaitlyn Cook; Rui Wang; Hsing-Ying Lin; Jan Van Deun; Huiyan Li; Jouha Min; Lan Wang; Ghilsuk Yoon; Bob S Carter; Leonora Balaj; Gyu-Seog Choi; Cesar M Castro; Ralph Weissleder; Hakho Lee Journal: Nat Biomed Eng Date: 2021-06-28 Impact factor: 25.671